Catalyst Pharmaceuticals Q2 EPS $0.53 Beats $0.42 Estimate, Sales $99.58M Beat $92.73M Estimate
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals reported Q2 earnings of $0.53 per share, beating the analyst consensus estimate of $0.42 by 26.19%. This is an 89.29% increase from the same period last year. The company also reported quarterly sales of $99.58 million, beating the analyst consensus estimate of $92.73 million by 7.39%. This is an 87.49% increase from the same period last year.
August 09, 2023 | 8:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals reported strong Q2 earnings and sales, both beating analyst estimates and showing significant YoY growth.
Catalyst Pharmaceuticals reported Q2 earnings and sales that beat analyst estimates by a significant margin. This strong performance, which also represents substantial YoY growth, is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100